Terns Pharma Analyst Ratings
Terns Pharma Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/27/2023 | 164.55% | Mizuho | $17 → $10 | Maintains | Buy |
08/10/2023 | 111.64% | HC Wainwright & Co. | $11 → $8 | Maintains | Neutral |
08/09/2023 | 191.01% | JP Morgan | $10 → $11 | Maintains | Neutral |
08/08/2023 | 508.47% | Roth MKM | → $23 | Reiterates | → Buy |
07/26/2023 | 349.74% | JMP Securities | → $17 | Reiterates | Market Outperform → Market Outperform |
06/30/2023 | 508.47% | Roth MKM | → $23 | Reiterates | Buy → Buy |
06/30/2023 | 349.74% | JMP Securities | → $17 | Reiterates | Market Outperform → Market Outperform |
06/30/2023 | 323.28% | Mizuho | → $16 | Reiterates | Buy → Buy |
06/27/2023 | 323.28% | Mizuho | → $16 | Reiterates | Buy → Buy |
06/22/2023 | 323.28% | Mizuho | → $16 | Initiates Coverage On | → Buy |
06/07/2023 | 376.19% | Jefferies | → $18 | Initiates Coverage On | → Buy |
05/31/2023 | 508.47% | Roth MKM | → $23 | Initiates Coverage On | → Buy |
05/19/2023 | 191.01% | HC Wainwright & Co. | → $11 | Reiterates | Neutral → Neutral |
05/16/2023 | 164.55% | JP Morgan | $9 → $10 | Maintains | Neutral |
05/16/2023 | 349.74% | JMP Securities | $17 → $17 | Reiterates | Market Outperform → Market Outperform |
05/08/2023 | 376.19% | BMO Capital | → $18 | Initiates Coverage On | → Outperform |
03/29/2023 | 349.74% | JMP Securities | → $17 | Reiterates | → Market Outperform |
03/29/2023 | 138.1% | JP Morgan | $6 → $9 | Maintains | Neutral |
03/29/2023 | 191.01% | HC Wainwright & Co. | $7 → $11 | Maintains | Neutral |
02/14/2023 | 349.74% | JMP Securities | → $17 | Initiates Coverage On | → Market Outperform |
02/07/2023 | 402.65% | UBS | → $19 | Initiates Coverage On | → Buy |
12/29/2022 | 85.19% | HC Wainwright & Co. | $6 → $7 | Maintains | Neutral |
12/20/2022 | 270.37% | Goldman Sachs | $9 → $14 | Maintains | Buy |
09/28/2022 | 138.1% | Goldman Sachs | $4 → $9 | Maintains | Buy |
09/12/2022 | 58.73% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Neutral |
03/23/2022 | 58.73% | JP Morgan | $19 → $6 | Downgrades | Overweight → Neutral |
08/18/2021 | 402.65% | JP Morgan | $32 → $19 | Maintains | Overweight |
03/02/2021 | 746.56% | JP Morgan | → $32 | Initiates Coverage On | → Overweight |
03/02/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
03/02/2021 | 667.2% | Goldman Sachs | → $29 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/27/2023 | 164.55% | 瑞穗市 | 17 美元 → 10 美元 | 维护 | 买 |
08/10/2023 | 111.64% | HC Wainwright & Co. | 11 美元 → 8 美元 | 维护 | 中立 |
08/09/2023 | 191.01% | 摩根大通 | 10 美元 → 11 美元 | 维护 | 中立 |
08/08/2023 | 508.47% | Roth MKM | → 23 美元 | 重申 | → 购买 |
07/26/2023 | 349.74% | JMP 证券 | → 17 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
06/30/2023 | 508.47% | Roth MKM | → 23 美元 | 重申 | 购买 → 购买 |
06/30/2023 | 349.74% | JMP 证券 | → 17 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
06/30/2023 | 323.28% | 瑞穗市 | → 16 美元 | 重申 | 购买 → 购买 |
06/27/2023 | 323.28% | 瑞穗市 | → 16 美元 | 重申 | 购买 → 购买 |
06/22/2023 | 323.28% | 瑞穗市 | → 16 美元 | 启动覆盖范围开启 | → 购买 |
06/07/2023 | 376.19% | 杰富瑞集团 | → 18 美元 | 启动覆盖范围开启 | → 购买 |
05/31/2023 | 508.47% | Roth MKM | → 23 美元 | 启动覆盖范围开启 | → 购买 |
05/19/2023 | 191.01% | HC Wainwright & Co. | → 11 美元 | 重申 | 中性 → 中性 |
05/16/2023 | 164.55% | 摩根大通 | 9 美元 → 10 美元 | 维护 | 中立 |
05/16/2023 | 349.74% | JMP 证券 | 17 美元 → 17 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
05/08/2023 | 376.19% | BMO Capital | → 18 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
03/29/2023 | 349.74% | JMP 证券 | → 17 美元 | 重申 | → 市场跑赢大盘 |
03/29/2023 | 138.1% | 摩根大通 | 6 美元 → 9 美元 | 维护 | 中立 |
03/29/2023 | 191.01% | HC Wainwright & Co. | 7 美元 → 11 美元 | 维护 | 中立 |
02/14/2023 | 349.74% | JMP 证券 | → 17 美元 | 启动覆盖范围开启 | → 市场跑赢大盘 |
02/07/2023 | 402.65% | 瑞银(UBS) | → 19 美元 | 启动覆盖范围开启 | → 购买 |
12/29/2022 | 85.19% | HC Wainwright & Co. | 6 美元 → 7 美元 | 维护 | 中立 |
2022 年 12 月 20 日 | 270.37% | 高盛 | 9 美元 → 14 美元 | 维护 | 买 |
2022 年 9 月 28 日 | 138.1% | 高盛 | 4 美元 → 9 美元 | 维护 | 买 |
09/12/2022 | 58.73% | HC Wainwright & Co. | → 6 美元 | 启动覆盖范围开启 | → 中立 |
03/23/2022 | 58.73% | 摩根大通 | 19 美元 → 6 美元 | 降级 | 超重 → 中性 |
2021 年 8 月 18 日 | 402.65% | 摩根大通 | 32 美元 → 19 美元 | 维护 | 超重 |
2021 年 2 月 3 日 | 746.56% | 摩根大通 | → 32 美元 | 启动覆盖范围开启 | → 超重 |
2021 年 2 月 3 日 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
2021 年 2 月 3 日 | 667.2% | 高盛 | → 29 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Terns Pharma (TERN)?
Terns Pharma(TERN)的目标价格是多少?
The latest price target for Terns Pharma (NASDAQ: TERN) was reported by Mizuho on November 27, 2023. The analyst firm set a price target for $10.00 expecting TERN to rise to within 12 months (a possible 164.55% upside). 23 analyst firms have reported ratings in the last year.
瑞穗于2023年11月27日公布了Terns Pharma(纳斯达克股票代码:TERN)的最新目标股价。该分析公司将目标股价定为10.00美元,预计TERN将在12个月内升至12个月内(可能上涨164.55%)。去年有23家分析公司公布了评级。
What is the most recent analyst rating for Terns Pharma (TERN)?
Terns Pharma(TERN)的最新分析师评级是多少?
The latest analyst rating for Terns Pharma (NASDAQ: TERN) was provided by Mizuho, and Terns Pharma maintained their buy rating.
瑞穗对Terns Pharma(纳斯达克股票代码:TERN)的最新分析师评级由瑞穗提供,Terns Pharma维持买入评级。
When is the next analyst rating going to be posted or updated for Terns Pharma (TERN)?
Terns Pharma(TERN)的下一次分析师评级何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Terns Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Terns Pharma was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Terns Pharma的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Terns Pharma的最新评级是在2023年11月27日公布的,因此您应该预计下一个评级将在2024年11月27日左右公布。
Is the Analyst Rating Terns Pharma (TERN) correct?
Terns Pharma(TERN)的分析师评级是否正确?
While ratings are subjective and will change, the latest Terns Pharma (TERN) rating was a maintained with a price target of $17.00 to $10.00. The current price Terns Pharma (TERN) is trading at is $3.78, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但Terns Pharma(TERN)的最新评级维持不变,目标股价为17.00美元至10.00美元。Terns Pharma(TERN)目前的交易价格为3.78美元,超出了分析师的预期区间。